Gentian Diagnostics

[Boms]

Arctic har en gammel analyse med target på ca 160,- kr.

[donkeykong]

Datert?

Har du den?

[Boms]

Er på reise, så har ikke tilgang til den nå. Sist oppdatert etter 1Q 2020 tror jeg.

[Quadruple]

Her intervjuer Artic CEO i Gentian:

CEO Interview at Arctic Securities

[Quadruple]

Artic hadde kursmål 170 allerede i 2018, men kursen har aldri vært over 80.

BørsXtra fredag: Arctic tror på 4-dobling i biotechselskap, nye...

[sparkonge]

Gentian eier PreTect som blir omtalt i denne artikkelen. Testen til PreTect er etter min mening veldig undervurdert.

En ekstra sjekk av celleprøven kan ha redda livet til Tonje

[Rubba]

Gentian selger datter for 7,7 millioner

[sparkonge]

Det salget hadde jeg ikke fått med meg. Takk for opplysningen!

[TekBot]

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021

Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody test project has moved from the proof-of-concept phase to the project initiation and optimisation phase. An official project plan has been established with an approved budget and a dedicated project team, moving the project forward. The timeline to launch is set to Q4 2021.
…

Vis børsmeldingen

The aim for the SARS-CoV-2 antibody test is to offer the first assay on high-throughput open-access clinical chemistry platforms, that supports vaccination efforts and aid in community management by the determination of immunisation status.

The project is supported by the collaboration with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway, providing expertise and guidance regarding SARS-CoV-2 research and vaccination trends.

Gentian’s CEO Dr. Hilja Ibert commented: “This is truly an outstanding achievement. Our R&D team has managed to bring this marker into the optimisation phase in record time and with the participation from our collaborating partners we will move forward with the assay development."

For further information contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

Kilde

[TekBot]

Presentation of 2020 fourth quarter results for Gentian Diagnostics AS

Gentian Diagnostics AS will present its 2020 fourth quarter results on February 11th at 09.00 am.

The presentation will be held as a webcast and participants are invited to register or join using the following link:
…

Vis børsmeldingen

https://attendee.gotowebinar.com/register/8677146068094125072

The webcast will be available on the company website after the presentation and will be hosted by Hilja Ibert, CEO and Njaal kind, CFO.

Kilde

[TekBot]

4Q 2020 Results and preliminary annual report

Moss, 11 February 2020

Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary annual results. The highlights include:
…

Vis børsmeldingen

• Gentian finished the year with record sales of MNOK 17.2 in the 4Q20 which corresponds to 22 % growth versus 4Q19

• Total sales revenue for the year was MNOK 63.3 representing a 32 % growth (22 % adjusted for currency effects) compared to the same period last year

• Double digit sales growth was achieved for all products and all regions in 2020

• Gentian’s unique PETIA-based SARS-CoV-2 antibody test has reached the next development phase with an estimated launch by the end of 2021

• Encouraging scientific publications on GCAL® in context of COVID-19 patient management have spurred the interest of hospitals and laboratories from all over Europe

Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

Kilde

[theroger]

Inntektshopp for Gentian Diagnostics

[TekBot]

Publication of NT-proBNP patent application

Moss, 18 February 2021

Gentian Diagnostics AS today announces that its patent application for a highly sensitive particle enhanced assay for the quantification of NT-proBNP has been published by the World Intellectual Property Organization (PCT Application No. PCT/EP2020/072720) with WIPO number: WO2021/028520. The technology described in this patent application enables Gentian to develop and commercialize an automated and fast NT-proBNP assay for open turbidimetric clinical chemistry platforms.
…

Vis børsmeldingen

The launch of the NT-proBNP assay, a biomarker to aid in the diagnosis of congestive heart failure (CHF), is planned for 4Q 2021. The assay under development by Gentian Diagnostics will enable improvement of laboratory productivity based on higher throughput in comparison to currently used assays and contribute to the harmonization and standardization of the NT-proBNP assays.

Going forward, the Company will announce when patents are granted.

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

Kilde

[TekBot]

Presentation of 2021 first quarter results for Gentian Diagnostics AS

Gentian Diagnostics AS will present its 2021 first quarter results on April 16th at 10.00 am.

The presentation will be held as a webcast and participants are invited to
…

Vis børsmeldingen

register or join using the following link

https://attendee.gotowebinar.com/register/3282011836850822413

The webcast will be available on the company website after the presentation and
will be hosted by Hilja Ibert, CEO and Njaal kind, CFO.

Kilde

[TekBot]

First quarter 2021 report

Moss, 16 April 2021

Gentian Diagnostics AS announces its results for the first quarter of 2021. The highlights include:
…

Vis børsmeldingen

• Record sales revenue of MNOK 19.6 in 1Q21, a 33 % organic growth. Reported growth of 24 % on a currency neutral basis as 1Q20 includes revenues from the subsidiary Pretect AS, which was divested in 2H20.

• Growth of 60 % versus Q1 last year in fCAL® turbo sales.

• Increased commercial momentum for GCAL®, displaying early signs of the next revenue level, with new routine users in several European countries and new distribution contracts.

• Expanded NT-proBNP development scope in order to enable industry standardisation, expected to positively impact adoption rates. New launch date set to 1Q22.

• Decision to apply for a listing of the shares at Oslo Børs Main market. It is envisaged that a transfer of the listing from Euronext Growth to the main market will take place towards the latter part of 1H21.

Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.

For further information, please contact:

Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525

Kilde

[TekBot]

Annual report 2020

The Board of Gentian Diagnostics AS has approved the Annual Report for 2020. The Annual Report is without changes from the preliminary Annual Accounts published on 11 February 2020.

Please find the Annual Report for 2020 enclosed. The document will also be made available on www.gentian.com.
…

Vis børsmeldingen

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

Kilde

[TekBot]

Notice of Annual General Meeting

The 2021 Annual General Meeting of Gentian Diagnostics AS will be held on 4 May 2021 at 10:00 (CEST) at Bjørnåsveien 5, 1596 Moss.

IMPORTANT INFORMATION REGARDING LIMITATION OF PHYSICAL PRESENCE
…

Vis børsmeldingen

Due to the COVID 19 pandemic, the board encourages shareholders to not physically attend the general meeting. Instead, shareholders are encouraged to authorize the chairperson of the board to vote on their behalf or use the enclosed proxy form. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance.

Physical attendance increases the risk of infection spreading. Gentian Diagnostics AS wants to contribute to reducing the spread of COVID 19 and we hope our shareholders will support this by not physically attending the general meeting.

Please find the notice including appendices enclosed. The document will also be made available on www.gentian.com.

Kilde

[TekBot]

2021 Annual general meeting - proposal from the nomination committee

Moss 29.04.21

Further to the stock exchange release dated 22.04.21 with a call for the 2021 annual general meeting.
…

Vis børsmeldingen

The proposal from the nomination committee is now available on the Company’s website: www.gentian.com

Kilde

[TekBot]

Minutes of Annual General Meeting

The Annual General Meeting of Gentian Diagnostics AS was held 4 May 2021. All proposed resolutions on the agenda were approved in accordance with the notice for the meeting, which were published on 22 April 2021.

Please find the minutes of the meeting enclosed.
…

Vis børsmeldingen

For further information, please contact:
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.com
Cell Phone. +47 919 06 525

Kilde

[TekBot]

Gentian Diagnostics ASA – conversion to public limited liability company registered

Moss, 7 May 2021

Reference is made to the stock exchange announcement made on 4 May 2021 by Gentian Diagnostics AS (the “Company”) regarding the annual general meeting held the same date.
…

Vis børsmeldingen

The resolutions made by the general meeting, inter alia amendments to the Company’s articles of association, including the conversion of the Company into a public limited liability company and change of company name have now been registered with the Norwegian Register of Business Enterprises. The new name of the Company is Gentian Diagnostics ASA.

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

Kilde